We are a blend of visionary scientists and entrepreneurial thinkers. Rooted in a public university, we thrive on collaboration and are driven by a commitment to shape a healthier, sustainable tomorrow.
In nature, proteins harvest solar energy, manufacture molecules, and transform chemical energy into work. Our scientists draw inspiration from nature as we seek to design equally useful molecules from scratch.
By unlocking the power of proteins, we are setting the stage for a new wave of medicines and materials with previously unimagined functions — tapping into the full efficiency, scalability, and sustainability of biology.
Our work extends far beyond our labs. From launching successful startups to developing a licensed vaccine for COVID-19, our science is shaping tomorrow.
Protein Therapeutics
Computer-generated molecules that reprogram cells, block infection, capture toxins & more.
Next-Generation Vaccines
Highly stable and customizable vaccines for influenza, HIV, cancer & beyond.
Advanced Drug Delivery
Nanoscale protein assemblies that move therapeutics to specific cells within the body.
Biological Devices
Programmable switches, sensors, and molecular machines that function inside cells.
Self-Assembling Nanomaterials
Atomically precise materials with applications in solar energy, imaging, and basic research.
Bioactive Peptides
Chemically synthesized molecules with predictable structures and functions.
Algorithm Development
Biomolecular modeling and computational design are at the heart of everything we do.
The Institute for Protein Design (IPD) is pleased to announce the appointment of Lynda Stuart, MD, PhD, as its new Executive Director. Dr. Stuart, an accomplished immunologist and former Deputy Director at the Bill & Melinda Gates Foundation, assumes her new role on May 1. Dr. Stuart is a physician, scientist, and advocate for healthcare […]
A protein-based vaccine for COVID-19 that uses our self-assembling nanoparticle technology has been approved abroad. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute vaccines around the world.
KumaMax is an enzyme designed to treat Celiac disease. Research on it began as an undergraduate project in the Baker Lab and would go on to form the basis of a spinout company. Takeda Pharmaceuticals is now working to test KumaMax into the clinic.
Computers are smart, but they sometimes miss important things. The same goes for researchers. This is where Foldit comes in: everyday people playing Foldit can help discover better protein designs through their unique creativity and ingenuity.